Đang chuẩn bị liên kết để tải về tài liệu:
The epigenetic immunomodulator, HBI8000, enhances the response and reverses resistance to checkpoint inhibitors
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Treatment with immune checkpoint inhibitors (ICIs) targeting CTLA-4 and the PD-1/PD-L1 axis is effective against many cancer types. However, due in part to unresponsiveness or acquired resistance, not all patients experience a durable response to ICIs. |